Singapore OKs OraQuick HIV test kit

5 August 2007

Singapore's Ministry of Health has issued a directive that allows the OraQuick Rapid HIV 1/2 Antibody Test Kits, developed by USA-based OraSure Technologies, to be used at all clinics in the country. The kit uses oral fluid for analysis in needle-free process, which is designed for patient convenience, that can produce definitive results in around 20 minutes.

Additionally, the directive permits the use of the OraQuick kit in the mandatory testing of foreign nationals who are seeking, or renewing, work permits. Douglas Michaels, chief executive of OraSure, welcomed the news, commented that its product, distributed by local firm Rockeby biomed, would make a substantial contribution towards HIV detection in Singapore.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight